Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $12 | $25 | $31 | $32 |
| Short-Term Investments | $121 | $208 | $171 | $259 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $3 | $3 | $4 |
| Total Curr. Assets | $136 | $236 | $204 | $295 |
| Property Plant & Equip (Net) | $35 | $38 | $7 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $4 | $4 | $9 | $4 |
| Total NC Assets | $40 | $42 | $16 | $10 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $176 | $278 | $221 | $305 |
| Liabilities | – | – | – | – |
| Payables | $8 | $5 | $7 | $8 |
| Short-Term Debt | $3 | $1 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $15 | $16 | $13 | $10 |
| Total Curr. Liab. | $26 | $22 | $22 | $19 |
| LT Debt | $15 | $15 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $3 | $3 | $0 |
| Total NC Liab. | $18 | $19 | $3 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $18 | $17 | $2 | $2 |
| Total Liabilities | $44 | $41 | $25 | $19 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$584 | -$456 | -$335 | -$219 |
| AOCI | $0 | $0 | -$2 | -$1 |
| Other Equity | $715 | $693 | $532 | $506 |
| Total Equity | $131 | $237 | $195 | $286 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $176 | $278 | $221 | $305 |
| Net Debt | $6 | -$8 | -$29 | -$30 |